Literature DB >> 2422582

The description and interpretation of aphasic language disorder.

J C Marshall.   

Abstract

The nature of aphasic impairment is reviewed from four viewpoints: (1) the construction of behavioural classifications that predict the locus of brain damage; (2) the initial assessment of a range of psycholinguistic functions sufficiently wide to detect the main outlines of deficit and preservation; (3) the elucidation of change in functional status, including both spontaneous and therapy-aided recovery; (4) the relationship between models of normal linguistic performance and the structure of pathological disorder. Arguments are provided against studies of aphasia based upon clinical (or other) taxonomies; arguments are given for the closer integration of analyses of normal and aphasic language.

Entities:  

Mesh:

Year:  1986        PMID: 2422582     DOI: 10.1016/0028-3932(86)90040-0

Source DB:  PubMed          Journal:  Neuropsychologia        ISSN: 0028-3932            Impact factor:   3.139


  4 in total

1.  Diagnosis, risk factors, and treatment of vascular dementia.

Authors:  Oscar L Lopez; Lewis H Kuller; James T Becker
Journal:  Curr Neurol Neurosci Rep       Date:  2004-09       Impact factor: 5.081

2.  Parallel functional category deficits in clauses and nominal phrases: The case of English agrammatism.

Authors:  Honglei Wang; Masaya Yoshida; Cynthia K Thompson
Journal:  J Neurolinguistics       Date:  2014-01       Impact factor: 1.710

3.  Masked priming effects in aphasia: evidence of altered automatic spreading activation.

Authors:  JoAnn P Silkes; Margaret A Rogers
Journal:  J Speech Lang Hear Res       Date:  2012-03-12       Impact factor: 2.297

4.  German Language Adaptation of the NAVS (NAVS-G) and of the NAT (NAT-G): Testing Grammar in Aphasia.

Authors:  Ruth Ditges; Elena Barbieri; Cynthia K Thompson; Sandra Weintraub; Cornelius Weiller; Marek-Marsel Mesulam; Dorothee Kümmerer; Nils Schröter; Mariacristina Musso
Journal:  Brain Sci       Date:  2021-04-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.